跳至主要内容
临床试验/NCT02949505
NCT02949505已完成不适用

Impact of Exercise Therapy on Functional Capacity in Patients Listed for Liver Transplantation

Matthew Armstrong1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2017年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
18
试验地点
1
主要终点
Number of participants with intervention-related adverse events as assessed by CTCAE v4.0

研究概览

简要总结

A UK prospective, single-centre feasibility study investigating the effects of exercise therapy on functional capacity in patients on the waiting list for liver transplantation. Patients will receive a 12-week home prehabilitation program (daily step program; functional resistance exercise sessions; telephone health call or virtual clinic). The following will be assessed at weeks 0, 6 and 12 weeks: feasibility (recruitment, compliance, safety, patients perception), functional capacity (ISWT, SPBT), psychological wellbeing (HADS questionnaire) and quality of life (EQ-5D)

详细描述

as above

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Meet the United Kingdom Liver Transplant criteria for listing
  • Accepted on the liver transplant waiting list for a primary transplant
  • Adults ≥18years who have an indication for a liver transplant
  • Diagnosed with sarcopenia at liver transplant assessment

排除标准

  • Significant cardiovascular instability including a recent Myocardial infarction, recent Cerebrovascular accident and/or a recent unstable arrhythmia
  • Unstable encephalopathy - open to interpretation by the chief investigator
  • Patient or next of kin non-English speaking
  • Inpatients
  • Refusal or lacks capacity to give informed consent

结局指标

主要结局

Number of participants with intervention-related adverse events as assessed by CTCAE v4.0

时间窗: 12-week

As this is a feasibility/Pilot study the investigators need to assess if any participants have any adverse events related to the home prehabilitation programme and if so, determine the severity and frequency

次要结局

未报告次要终点

研究者

发起方
Matthew Armstrong
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Matthew Armstrong

Principal investigator, Specialist Registrar in Hepatology and Honorary Clinical Fellow

University of Birmingham

研究点 (1)

Loading locations...

相似试验